Inovio reports clinical success for cervical cancer vax

Inovio Pharmaceuticals says its DNA cervical cancer vaccine produced promising results in an early-stage study, with one dose group registering "unprecedented T-cell responses" for five out of six patients. The vaccine company says that VGX-3100, its vaccine to treat precancerous cervical dysplasias and cervical cancers caused by human papillomavirus types 16 and 18, will be ready to go into Phase II in the first quarter of next year. Inovio release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.